Massachusetts Eye Research and Surgery Institution, Cambridge, Massachusetts 02142, USA.
Ocul Immunol Inflamm. 2013;21(1):47-52. doi: 10.3109/09273948.2012.728668.
To compare the efficacy and safety of cyclosporine/mycophenolate mofetil (CSA/MMF) and cyclosporine/azathioprine (CSA/AZT) in Vogt-Koyonagi-Harada (VKH) patients.
Retrospective comparative case series with follow-up period of at least 1 year. Outcomes include remission rate and corticosteroid-sparing effect.
A total of 10 patients were included (5 patients in CSA/MMF, 5 patients in CSA/AZT). The remission rates for CSA/MMF and CSA/AZT were 5.3 and 5.6, respectively (p = .96). The median time to remission was 15 months for CSA/MMF group and 7 months for CSA/AZT group (p = .6419). The rates of corticosteroid-sparing effect were 7.9 and 5.0 for the CSA/MMF and CSA/AZT groups, respectively (p = .65). The median time to corticosteroid-sparing effect was faster in the CSA/AZT group (2 months) compared to the CSA/MMF group (13 months) (p = .9625). Approximately 50% of patients failed with the presented IMT combination regimens.
No statistically significant difference was found in the two regimens from the study as presented, although the median time to remission and to corticosteroid-sparing effect was shorter for the CSA/AZT combination.
比较环孢素/霉酚酸酯（CSA/MMF）与环孢素/硫唑嘌呤（CSA/AZT）在 Vogt-Koyonagi-Harada（VKH）患者中的疗效和安全性。
回顾性对比病例系列研究，随访期至少 1 年。结局包括缓解率和皮质类固醇激素节省效应。
共纳入 10 例患者（CSA/MMF 组 5 例，CSA/AZT 组 5 例）。CSA/MMF 和 CSA/AZT 的缓解率分别为 5.3%和 5.6%（p =.96）。CSA/MMF 组缓解的中位数时间为 15 个月，CSA/AZT 组为 7 个月（p =.6419）。CSA/MMF 和 CSA/AZT 组的皮质类固醇激素节省效应率分别为 7.9%和 5.0%（p =.65）。CSA/AZT 组达到皮质类固醇激素节省效应的中位数时间快于 CSA/MMF 组（2 个月比 13 个月）（p =.9625）。大约 50%的患者对所提出的 IMT 联合方案治疗失败。
尽管 CSA/AZT 联合方案的缓解时间和皮质类固醇激素节省效应的中位数时间较短，但从研究结果来看，两种方案之间没有统计学上的显著差异。
